ReviewExpert review of respiratory medicine2018
Cystic fibrosis respiratory microbiota: unraveling complexity to inform clinical practice.
Review in Expert review of respiratory medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 46 citations in OpenAlex.
- From colonisation to chronicity: adaptation ofMicrobiology (Reading, England) · 2026Article
- Modulation of host inflammatory pathways byFrontiers in immunology · 2026Article
- Review
- Harnessing hypoxia: bacterial adaptation and chronic infection in cystic fibrosis.FEMS microbiology reviews · 2025Review
- Microbial community organization designates distinct pulmonary exacerbation types and predicts treatment outcome in cystic fibrosis.Nature communications · 2024Observational
- Microbial community organization designates distinct pulmonary exacerbation types and predicts treatment outcome in cystic fibrosis.Research square · 2024Article
- Changes in upper airways microbiota in ventilator-associated pneumonia.Intensive care medicine experimental · 2023Article
- SARS-CoV-2 Infection in Patients with Cystic Fibrosis: What We Know So Far.Life (Basel, Switzerland) · 2022Review
- Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome.Microbiology spectrum · 2022Article
- Low Diversity and Instability of the Sinus Microbiota over Time in Adults with Cystic Fibrosis.Microbiology spectrum · 2022Article
- Biofilm aggregates and the host airway-microbial interface.Frontiers in cellular and infection microbiology · 2022Review
- Cystic fibrosis airway microbiota associated with outcomes of nontuberculous mycobacterial infection.ERJ open research · 2021Article
- Impact ofJournal of clinical medicine · 2020Review
- Longitudinal monitoring of sinonasal and oral bacterial reservoirs to prevent chronic lung infection in people with cystic fibrosis.ERJ open research · 2020Article
- Article
- The future of cystic fibrosis care: a global perspective.The Lancet. Respiratory medicine · 2020Review
- The Lung Microbiome of Three Young Brazilian Patients With Cystic Fibrosis Colonized by Fungi.Frontiers in cellular and infection microbiology · 2020Article
- Longitudinal Associations of the Cystic Fibrosis Airway Microbiome and Volatile Metabolites: A Case Study.Frontiers in cellular and infection microbiology · 2020Article
- Article
- Measures of Cystic Fibrosis Airway Microbiota during Periods of Clinical Stability.Annals of the American Thoracic Society · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
introductionCystic fibrosis (CF) lung disease is characterized by chronic cycles of pulmonary infection, inflammation, and mucus obstruction, beginning early in life, and eventually leading to progressive lung damage and early mortality. During the past ~15 years, culture-independent analyses of CF respiratory samples have identified diverse bacterial communities in CF airways, and relationships between respiratory microbiota and clinical outcomes. Areas covered: This paper reviews recent advances in our understanding of the relationships between respiratory microbiota and CF lung disease. The paper focuses on measures of airway bacterial community diversity and estimates of the relative abundance of anaerobic species. Finally, this paper will review the opportunities for advancing patient care suggested by these studies and highlight some of the ongoing challenges and unmet needs in translating this knowledge into clinical practice. Expert commentary: Culture-independent analyses of respiratory microbiota have suggested new strategies for advancing CF care, but have also highlighted challenges in understanding the complexity of CF respiratory infections. Development of more sophisticated models and analytic approaches to better account for this complexity are needed to elucidate mechanistic links between CF respiratory microbiota and clinical outcomes, and to ultimately translate this knowledge into better patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.